KR102770106B1 - Cd38 조정 항체 - Google Patents

Cd38 조정 항체 Download PDF

Info

Publication number
KR102770106B1
KR102770106B1 KR1020207000247A KR20207000247A KR102770106B1 KR 102770106 B1 KR102770106 B1 KR 102770106B1 KR 1020207000247 A KR1020207000247 A KR 1020207000247A KR 20207000247 A KR20207000247 A KR 20207000247A KR 102770106 B1 KR102770106 B1 KR 102770106B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
sequence
antigen
acd38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000247A
Other languages
English (en)
Korean (ko)
Other versions
KR20200021068A (ko
Inventor
파스칼 머치어스
앤 구비어
케빈 모울더
니나 아이슬러
조세핀 살리무
시몬 플로스토
비트리즈 고예네체아 코르조
헤만타 바루아
비안카 프린즈
Original Assignee
블랙 벨트 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블랙 벨트 테라퓨틱스 리미티드 filed Critical 블랙 벨트 테라퓨틱스 리미티드
Priority to KR1020257004706A priority Critical patent/KR20250025514A/ko
Publication of KR20200021068A publication Critical patent/KR20200021068A/ko
Application granted granted Critical
Publication of KR102770106B1 publication Critical patent/KR102770106B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207000247A 2017-06-08 2018-06-08 Cd38 조정 항체 Active KR102770106B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257004706A KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,149 2017-06-08
US62/517,150 2017-06-08
US201762517745P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US62/517,734 2017-06-09
US62/517,745 2017-06-09
US62/517,165 2017-06-09
US62/517,164 2017-06-09
US62/517,753 2017-06-09
US62/517,740 2017-06-09
US201762582653P 2017-11-07 2017-11-07
US201762582666P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US62/582,653 2017-11-07
US62/582,681 2017-11-07
US62/582,676 2017-11-07
US62/582,666 2017-11-07
PCT/EP2018/065239 WO2018224683A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257004706A Division KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Publications (2)

Publication Number Publication Date
KR20200021068A KR20200021068A (ko) 2020-02-27
KR102770106B1 true KR102770106B1 (ko) 2025-02-21

Family

ID=62620847

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207000247A Active KR102770106B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020257004706A Pending KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020207000253A Active KR102719065B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257004706A Pending KR20250025514A (ko) 2017-06-08 2018-06-08 Cd38 조정 항체
KR1020207000253A Active KR102719065B1 (ko) 2017-06-08 2018-06-08 Cd38 조정 항체

Country Status (8)

Country Link
US (3) US12343394B2 (enExample)
EP (2) EP3635002A1 (enExample)
JP (3) JP7237951B2 (enExample)
KR (3) KR102770106B1 (enExample)
CN (2) CN110997722B (enExample)
AU (3) AU2018280871B2 (enExample)
CA (2) CA3066553A1 (enExample)
WO (2) WO2018224683A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224683A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
EP3914616A1 (en) 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
CA3133078A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
CN113874397A (zh) 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
CN114524877A (zh) * 2019-03-29 2022-05-24 索伦托药业有限公司 结合cd38的经工程改造的变异抗体
KR20230066404A (ko) 2020-09-10 2023-05-15 카시 파마슈티컬스, 인코포레이티드 혈액 스크리닝 방법
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504801A (ja) 2008-10-06 2012-02-23 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア ミスフォールドタンパク質エピトープを予測するための方法およびシステム
WO2016071355A1 (en) 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
AU2011202520C1 (en) 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
WO2006113747A2 (en) * 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
AU2016228249A1 (en) 2006-09-26 2016-10-06 Genmab A/S Combination treatment of CD38-expressing tumors
AU2013209322A1 (en) 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
EP2097534A4 (en) 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
CN101605906A (zh) 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP5746183B2 (ja) 2009-09-22 2015-07-08 プロビオゲン アーゲー 特定のグリカン構造を含有する分子を生成する方法
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
GB201300346D0 (en) * 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN105143265A (zh) 2013-03-15 2015-12-09 豪夫迈·罗氏有限公司 抗CRTh2抗体及其用途
EP3104882B1 (en) 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
EP3226892A4 (en) 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
CN107921122B (zh) 2015-04-08 2021-08-10 索伦托药业有限公司 与cd38结合的抗体治疗剂
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2016210223A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
WO2018224683A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
WO2021057978A1 (zh) * 2019-09-27 2021-04-01 南京金斯瑞生物科技有限公司 抗vhh域抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012504801A (ja) 2008-10-06 2012-02-23 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア ミスフォールドタンパク質エピトープを予測するための方法およびシステム
WO2016071355A1 (en) 2014-11-04 2016-05-12 Glenmark Pharmaceuticals S.A. Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, Vol. 20, No. 17, pp. 4574-4583 (2014)*

Also Published As

Publication number Publication date
AU2018280869A1 (en) 2020-01-16
WO2018224683A1 (en) 2018-12-13
AU2025201908A1 (en) 2025-04-03
CN110997722A (zh) 2020-04-10
CA3066553A1 (en) 2018-12-13
JP2020522280A (ja) 2020-07-30
US12343394B2 (en) 2025-07-01
AU2018280869B2 (en) 2025-01-02
KR20200021069A (ko) 2020-02-27
KR20200021068A (ko) 2020-02-27
CN110997723B (zh) 2023-09-26
US20210277138A1 (en) 2021-09-09
JP2020522281A (ja) 2020-07-30
CN110997723A (zh) 2020-04-10
WO2018224685A1 (en) 2018-12-13
NZ760342A (en) 2025-03-28
US20230103584A1 (en) 2023-04-06
JP7237950B2 (ja) 2023-03-13
EP3635002A1 (en) 2020-04-15
NZ760448A (en) 2025-03-28
JP7237951B2 (ja) 2023-03-13
US20250367286A1 (en) 2025-12-04
EP3635003A1 (en) 2020-04-15
US12161717B2 (en) 2024-12-10
KR20250025514A (ko) 2025-02-21
JP2023030071A (ja) 2023-03-07
AU2018280871B2 (en) 2024-09-26
AU2018280871A8 (en) 2020-01-30
JP7467584B2 (ja) 2024-04-15
AU2018280871A1 (en) 2020-01-16
CN110997722B (zh) 2023-09-26
CA3066555A1 (en) 2018-12-13
KR102719065B1 (ko) 2024-10-17

Similar Documents

Publication Publication Date Title
KR102770106B1 (ko) Cd38 조정 항체
US20240092928A1 (en) Cd38 modulating antibody
US12162949B2 (en) CD38 antibody
US12304964B2 (en) CD38 modulating antibody
US11542338B2 (en) CD38 modulating antibody
KR102770104B1 (ko) Cd38 조정 항체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210607

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230821

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241125

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241218

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250213

PG1601 Publication of registration